announced Tuesday that longtime board member Judith McHale is retiring in May and that its board has tapped former Yahoo President and CEO Marissa Mayer to replace her. Mayer, 49, would bring ...

March 04, 2025--(BUSINESS WIRE)--The Board of Directors of Hilton Worldwide Holdings Inc. (NYSE: HLT) today announced that veteran business leader and technology entrepreneur Marissa Mayer has ...

--(BUSINESS WIRE)--The Board of Directors of Hilton Worldwide Holdings Inc. (NYSE: HLT) today announced that veteran business leader and technology entrepreneur Marissa Mayer has been nominated to ...

The former Google and Yahoo executive believes AI should simplify our lives but warns the real battle for the future will be determined by how the US and China embrace this technology. Marissa ...

The nomination of Marissa Mayer to the board adds technological expertise to Hilton, potentially boosting investor confidence. Her influence in tech-driven consumer applications could benefit the ...

When former Yahoo CEO Marissa Mayer tweeted about the launch of her new app, some people roasted Shine's outdated aesthetic and questioned the purpose of the photo-sharing app. Shine was the third ...

In the latest trading session, Gilead Sciences (GILD) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day.

The most recent trading session ended with Gilead Sciences (GILD) standing at $105.87, reflecting a -1.53% shift from the previouse trading day's closing. This change lagged the S&P 500's daily ...

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published ...

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...